The Radiolabeling, Quality Assurance, and Immunoassay Core will provide a variety of services for theparticipants of this Program Project. This Core Facility has been providing these same services to CMMIinvestigators for 20 years. The primary responsibility of this core involves the preparation of radiolabeledagents for investigators. This includes the processing, receipt, preparation, quality assurance and disposal ofthe radiolabeled materials. This laboratory has experience in preparing radiolabeled antibodies and peptideswith 1311,1251,123I, ' V 90Y, 188Re, 99mTc, 212Bi, and 67Ga. Each product that is produced undergoes a seriesof quality assurance checks, including ITLC, size-exclusion HPLC, and Immunoreactivity determinations.All equipment used in this laboratory is calibrated regularly and all procedures are performed under SOPs.This laboratory also produces radiolabeled investigational agents for a number of INDs, and has experiencein developing procedures to ensure product stability when shipped to extramural investigational sites. Thiscore is also involved in the processing of blood and urine samples used for pharmacokinetic analysis, as wellas plasma samples for anti-antibody assays. This Core will be utilized by Projects 1,2, and 4.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA103985-04
Application #
7728852
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-08-01
Project End
2009-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
4
Fiscal Year
2008
Total Cost
$127,805
Indirect Cost
Name
Center for Molecular Medicine/Immunology
Department
Type
DUNS #
118870583
City
Morris Plains
State
NJ
Country
United States
Zip Code
07950
Smith, Mitchell R; Jin, Fang; Joshi, Indira (2014) Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-?B dependent human transformed follicular lymphoma cell line. Br J Haematol 165:151-3
Binsky-Ehrenreich, I; Marom, A; Sobotta, M C et al. (2014) CD84 is a survival receptor for CLL cells. Oncogene 33:1006-16
Chen, X; Chang, C-H; Stein, R et al. (2012) The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD. Bone Marrow Transplant 47:967-80
Alinari, Lapo; Yu, Bo; Christian, Beth A et al. (2011) Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 117:4530-41
Brem, Elizabeth A; Thudium, Karen; Khubchandani, Sapna et al. (2011) Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol 153:599-611
Sharkey, Robert M; Goldenberg, David M (2011) Cancer radioimmunotherapy. Immunotherapy 3:349-70
Stein, Rhona; Balkman, Cheryl; Chen, Susan et al. (2011) Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma. Leuk Lymphoma 52:273-84
Rossi, Edmund A; Rossi, Diane L; Cardillo, Thomas M et al. (2011) Preclinical studies on targeted delivery of multiple IFN?2b to HLA-DR in diverse hematologic cancers. Blood 118:1877-84
Olejniczak, Scott H; Blickwedehl, Jennifer; Belicha-Villanueva, Alan et al. (2010) Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood 116:5605-14
Gupta, Pankaj; Goldenberg, David M; Rossi, Edmund A et al. (2010) Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 116:3258-67

Showing the most recent 10 out of 43 publications